GT Biopharma Q2 FY26 net loss narrows to $4.5 million; operating loss widens to $4.5 million
Reuters2026/08/14 12:03- GT Biopharma posted a Q2 operating loss of $4.5 million, widening from $1.5 million a year earlier.
- Net loss was $4.5 million, narrowing from $30.2 million in the prior-year quarter due to a $28.7 million non-cash Greenshoe Rights liability then.
- R&D expenses climbed to $1.1 million from $0.4 million, driven by higher materials and production costs.
- SG&A expenses rose to $3.4 million from $1.1 million on higher marketing spend, with legal and consulting fees also up.
- Cash and cash equivalents were about $5.1 million at June 30, 2026, seen funding operations through Q4 2026; Phase 1 updates for GTB-3650 and GTB-5550 are expected in 2H 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan: Tesla (TSLA.US) Robotaxi revenue may reach $320 billions by 2035, with nearly 98% coming from its own fleet
JPMorgan analyst Rajat Gupta released a research report last week, estimating that by 2035, Tesla's Robotaxi revenue will reach approximately $320 billion, with nearly $314 billion coming from Tesla's own and operated fleet, rather than from the owner-operated "Tesla Network."
FDA approves Telix brain cancer imaging drug Pixclara for glioma PET scans
Charles Hoskinson Says AI Has Destroyed The Old Crypto Growth Metric
Kvika appoints Jón Birgir Jónsson as CEO, effective Dec. 1
Crypto prices
More
